<SEC-DOCUMENT>0001628280-26-011971.txt : 20260226
<SEC-HEADER>0001628280-26-011971.hdr.sgml : 20260226
<ACCEPTANCE-DATETIME>20260226070949
ACCESSION NUMBER:		0001628280-26-011971
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260226
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260226
DATE AS OF CHANGE:		20260226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			C4 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001662579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				475617627
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39567
		FILM NUMBER:		26681683

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 120
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 231-0700

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 120
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cccc-20260226.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:489cd0e9-8998-49cb-9345-9e2c9605a12d,g:745d9eba-1cd4-4395-9e30-128e31bdc431,d:c852c9a290634a10a8405bd6b4c133f6-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cccc-20260226</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001662579</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cccc-20260226.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001662579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-26</xbrli:startDate><xbrli:endDate>2026-02-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic852c9a290634a10a8405bd6b4c133f6_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February 26, 2026</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">C4 THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:32.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39567</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">47-5617627</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">490 Arsenal Way,</ix:nonNumeric>&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 120</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Watertown,</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02472</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">231-0700</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________________</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:4.080%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:38.617%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;padding-right:-1.31pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;padding-right:-1.31pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.1pt;padding-right:-1.31pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.1pt;padding-right:-1.31pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">CCCC</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><div style="margin-bottom:0.1pt;padding-right:-1.31pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#212529;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table><span style="color:#212529;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div></div><div id="ic852c9a290634a10a8405bd6b4c133f6_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2026, C4 Therapeutics, Inc. (the &#8220;</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Company</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) issued a press release announcing its financial results and business highlights for the quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="ic852c9a290634a10a8405bd6b4c133f6_19"></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><div style="margin-bottom:0.1pt;padding-right:-1.31pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:133%">Description</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">99.1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cccc-20260226xexx991.htm">Press release issued February 26, 2026</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">104</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div></div><div id="ic852c9a290634a10a8405bd6b4c133f6_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:0.1pt;margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"/><td style="width:47.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">C4 Therapeutics, Inc.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">Date: </span><span style="color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">February&#160;26, 2026</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">By:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:133%">/s/ Kendra R. Adams</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Kendra R. Adams</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:133%">Chief Financial Officer and Treasurer</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cccc-20260226xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="ic3f1345ce1f24ec68191bedb7d05d965_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:6pt"><img alt="c4tlogo1.jpg" src="c4tlogo1.jpg" style="height:28px;margin-bottom:5pt;vertical-align:text-bottom;width:187px"></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval&#59; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Strong Balance Sheet Provides Runway to the End of 2028&#59; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025 </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq&#58; CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the year ended December 31, 2025, as well as business updates. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We made significant progress in 2025, notably demonstrating cemsidomide&#8217;s best-in-class potential, establishing an efficient and differentiated regulatory path for cemsidomide, and extending our cash runway beyond key value&#8209;inflection milestones, further positioning us to become a fully integrated biopharmaceutical company,&#8221; said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. &#8220;As cemsidomide progresses into later-stage clinical trials across multiple lines of therapy in multiple myeloma, we believe it is well positioned to become the IKZF1&#47;3 degrader of choice. We continue to advance our discovery strategy, focused on targets that have a strong degrader rationale with first-in-class potential in inflammation, neuroinflammation and neurodegeneration diseases. Together, these achievements will bring us closer to delivering transformative TPD medicines for patients with significant unmet needs.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FOURTH QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In February 2026, the first patient was dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in the fourth line or later MM setting. The MOMENTUM trial was designed for potential accelerated approval with a recommended Phase 2 dose of 100 &#181;g. The trial will enroll approximately 100 patients with enrollment expected to be completed in Q1 2027.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In October 2025, C4T entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO&#174;), a B-cell maturation antigen CD3 targeted bispecific antibody, for the upcoming Phase 1b trial of cemsidomide in combination with elranatamab in earlier lines of MM treatment. C4T has continued to execute operational steps necessary for the initiation of the Phase 1b trial, which is expected in Q2 2026.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In October 2025, C4T raised $125 million in gross proceeds through an underwritten offering with the potential to earn up to $225 million in additional proceeds if the outstanding warrants are exercised. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In January 2026, C4T earned a $2 million milestone payment from Biogen related to BIIB145, a BTK degrader, designed by C4T and delivered to Biogen for clinical development. This is the second degrader that Biogen has advanced into the clinic under the Biogen and C4T collaboration.   </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">KEY UPCOMING MILESTONES</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Cemsidomide&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> IKZF1&#47;3 Degrader for Relapsed Refractory Multiple Myeloma (RRMM) </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">On track to initiate the Phase 1b trial of cemsidomide in combination with elranatamab in Q2 2026 with plans to provide incremental progress throughout 2026. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Present further analysis of the data from the completed Phase 1 trial of cemsidomide in combination with dexamethasone in mid-2026. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Share the plan to initiate an additional Phase 1b trial to evaluate cemsidomide in combination with other anti-myeloma agents in mid-2026. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">CFT8919&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> EGFR L858R Degrader for Non-Small-Cell Lung Cancer (NSCLC) </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">By end of Q1 2026, utilize data from the Phase 1 dose escalation trial conducted by Betta Pharmaceuticals to inform potential ex-China clinical development. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Research &#38; Discovery&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Internal Discovery Efforts Focused on Inflammation, Neuroinflammation &#38; Neurodegeneration (INN) with Collaboration Efforts Focused on Oncology &#38; Non-oncology  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Optimize indication selection for multiple targets across discovery portfolio focused on INN in 2026. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Deliver at least one development candidate to a collaboration partner by year-end 2026. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advance existing collaborations toward key milestones by year-end 2026. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">UPCOMING INVESTOR EVENTS&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">March 3, 2026, at 11&#58;50 AM ET&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Management will participate in a presentation and fireside chat at the TD Cowen 46th Annual Health Care Conference taking place in Boston, Massachusetts. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">March 10, 2026, at 8&#58;00 AM ET&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Management will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference taking place in Miami, Florida. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Revenue&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Total revenue for the fourth quarter and full year ended December 31, 2025, was $11.0 million and $35.9 million, respectively, compared to $5.2 million and $35.6 million for the prior year periods. The increase in revenue for the fourth quarter of 2025, as compared to the prior year period, reflects the prioritization of one KRAS project under the collaboration with Merck KGaA, Darmstadt, Germany.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development (R&#38;D) Expense&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">R&#38;D expense for the fourth quarter and full year ended December 31, 2025, was $25.0 million and $104.2 million, respectively, compared to $32.5 million and $110.6 million for the prior year periods. The decrease in R&#38;D expense for the fourth quarter of 2025, as compared to the prior year period, was primarily related to the completion of the CFT1946 Phase 1 clinical trial.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">General and Administrative (G&#38;A) Expense&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">G&#38;A expense for the fourth quarter and full year ended December 31, 2025, was $9.2 million and $36.2 million, respectively, compared to $10.4 million and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">$42.1 million for the prior year periods. The decrease in G&#38;A expense for the fourth quarter of 2025, as compared to the prior year period, was primarily related to lower stock-based compensation expense.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss and Net Loss per Share&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Net loss for the fourth quarter and full year ended December 31, 2025, was $20.5 million and $105.0 million, respectively, compared to $34.6 million and $105.3 million for the prior year periods. Net loss per share for the fourth quarter and full year ended December 31, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2025, was $0.18 and $1.27, respectively, compared to $0.49 and $1.52 for the prior year periods.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cash Position and Financial Guidance&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities as of December 31, 2025, was $297.1 million, compared to $199.8 million as of September 30, 2025, and $267.3 million as of December 31, 2024. The increase in cash, cash equivalents and marketable securities during 2025 was primarily the result of the net proceeds from the October equity offering partially offset by the cash used to fund operations and advance our programs. The company expects that its current cash, cash equivalents and marketable securities will enable it to fund its operating plan to the end of 2028.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">About Cemsidomide</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Cemsidomide is an investigational, orally bioavailable molecular glue degrader (MonoDAC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> degrader) of IKZF1&#47;3, transcription factors foundational to multiple myeloma biology. Data from the Phase 1 trial, which has completed enrollment, show cemsidomide&#8217;s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that support the potential for durable outcomes.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">About the MOMENTUM Trial</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">MOMENTUM (Multi-center trial Of cemsidoMidE iN relapsed&#47;refracTory mUltiple Myeloma) is a Phase 2, open-label, single-arm study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of cemsidomide in combination with dexamethasone in patients with relapsed&#47;refractory multiple myeloma. Data from the Phase 1 trial identified 100 &#181;g as the recommended Phase 2 dose. The primary endpoint is overall response rate per International Myeloma Working Group response criteria, as assessed by an independent review committee. Approximately 100 patients who have received at least three prior anti-myeloma regimens that must have included an IKZF1&#47;3 degrader, a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager or CAR-T therapy will be enrolled in the trial. More information is available at clinicaltrials.gov (NCT07284758). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">About Cemsidomide in Combination With Elranatamab (ELREXFIO&#174;) </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">The Phase 1b trial is designed to evaluate the safety, tolerability and preliminary efficacy of cemsidomide in combination with elranatamab, an FDA-approved B-cell maturation antigen CD3 targeted bispecific antibody. The study will evaluate different cemsidomide dose levels (beginning with 75 &#181;g, with the opportunity to simultaneously explore 50 &#181;g and 100 &#181;g) in patients who have received one to four prior lines of therapy, which must have consisted of at least one IKZF1&#47;3 degrader. Exclusion criteria for patients include those who have received prior treatment with a BCMA-directed T-cell engager or BCMA-directed CAR-T therapy. More information is available at clinicaltrials.gov (NCT07280013). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">About Multiple Myeloma</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Approved IKZF1&#47;3 degraders remain foundational therapies across lines of MM treatment. Despite advances, including immune-directed approaches, most patients ultimately relapse, underscoring a growing need for new therapeutics options that continue to leverage IKZF1&#47;3 degradation to drive myeloma cell death and T-cell activation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">About C4 Therapeutics</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">C4 Therapeutics (C4T) (Nasdaq&#58; CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients&#8217; lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO&#174; platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T&#8217;s degrader medicines are designed to harness the body&#8217;s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements&#8221; of C4 Therapeutics, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients&#59; the design and potential efficacy of our therapeutic approaches&#59; the predictive capability of our TORPEDO&#174; platform in the development of novel, selective, orally bioavailable BiDAC&#8482; and MonoDAC&#174; degraders&#59; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement and patient enrollment&#59; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials&#59; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials&#59; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials&#59; regulatory developments in the United States and foreign countries&#59; the anticipated timing and content of presentations of data from our clinical trials&#59; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to&#58; uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates&#59; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized&#59; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in C4 Therapeutics&#8217; most recent Annual Report on Form 10-K and&#47;or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Contacts&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"><br>Investors&#58;<br>Courtney Solberg<br>Associate Director, Investor Relations<br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CSolberg&#64;c4therapeutics.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Media&#58;<br>Loraine Spreen<br>Senior Director, Corporate Communications &#38; Patient Advocacy<br></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LSpreen&#64;c4therapeutics.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic3f1345ce1f24ec68191bedb7d05d965_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheet Data</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;text-align:right"><font><br></font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:63.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2025</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#14232c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">297,100&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">267,263&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#14232c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">359,075&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">349,602&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">28,334&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">47,169&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#14232c;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">256,587&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">215,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaboration agreements</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11,016&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,947&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">35,584&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24,982&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">32,513&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104,240&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">110,637&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">36,196&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,124&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,733&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,437&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,161&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,886&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">151,169&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">155,198&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(23,145)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(37,709)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(115,222)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(119,614)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,349&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,429&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">10,349&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">14,429&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(20,365)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(34,442)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(104,873)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(105,185)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(131)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(121)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(131)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(20,486)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(34,573)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(104,994)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(105,316)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share &#8722; basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.27)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8722; basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,784,306&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">70,606,156&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82,894,459&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">69,372,993&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cccc-20260226.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:489cd0e9-8998-49cb-9345-9e2c9605a12d,g:745d9eba-1cd4-4395-9e30-128e31bdc431-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cccc="http://c4therapeutics.com/20260226" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://c4therapeutics.com/20260226">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20260226_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cccc-20260226_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://c4therapeutics.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cccc-20260226_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:489cd0e9-8998-49cb-9345-9e2c9605a12d,g:745d9eba-1cd4-4395-9e30-128e31bdc431-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_0fe435e2-0e7d-45b3-b441-194f3038510b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1de1ff37-5640-412f-9ce9-b13c87a0b337_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6555cb4f-b5ba-4df6-9b1e-64447e9ac595_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3fc7d9bb-d632-4ae4-8428-883cf3667faf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_35287dac-1ebc-46c9-8639-d82fac58b7bf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6eae9c58-0ca7-46ab-a639-a05fcd7e34e7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cde78d36-1634-4fb5-8fec-f5726805f5c6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_4065330e-fb93-47a8-8259-ec61e985389b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fa30a80c-d14e-4124-8d16-9d44403f8ff5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ddc3dd91-1473-43e9-b4e5-656d6b7ce196_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8a8f847c-c092-46f0-9365-dc8ba4b5878b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4fd92840-c2b8-473c-9967-d466fdfe18fd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_437de4f1-3176-4821-aa2c-93820933ef6d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0be1b72e-cb9b-4703-845b-a5100fa69c8c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_96d87a24-db96-4362-8341-25da269770e7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a981dcc3-772a-4d73-88f6-f37dba899085_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_61c2204a-6903-4dbd-8a3e-dfd3e42398c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2b5c255d-5df9-4fc9-8fea-100ee37892db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8f1c6e77-3c58-4147-bc7c-044aa4d80f44_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_10866785-a3ff-4127-9de6-7a4a62e2d698_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_372c0402-2b3b-4cae-8d89-2ac2f2eb359a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a0ec9b22-4813-4d3c-8c12-0e6a25c000ba_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5be31880-6182-4821-88ae-2725789eb07e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cccc-20260226_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:489cd0e9-8998-49cb-9345-9e2c9605a12d,g:745d9eba-1cd4-4395-9e30-128e31bdc431-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://c4therapeutics.com/role/CoverPageDocument" xlink:type="simple" xlink:href="cccc-20260226.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://c4therapeutics.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_53ba500b-40af-480d-9407-9c88ff3d7f27" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_DocumentType_53ba500b-40af-480d-9407-9c88ff3d7f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ac0f68bc-85cc-41d8-9194-24de599e799f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_DocumentPeriodEndDate_ac0f68bc-85cc-41d8-9194-24de599e799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fa022226-6d16-43bb-b574-9db22ec89884" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityRegistrantName_fa022226-6d16-43bb-b574-9db22ec89884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_52e60566-4dac-458d-b3fb-d80b821c477b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_52e60566-4dac-458d-b3fb-d80b821c477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2956ccab-8e72-4f3a-8b2b-f4e2dbe2b9d5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityFileNumber_2956ccab-8e72-4f3a-8b2b-f4e2dbe2b9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d2e26dbe-6d45-4e55-933e-992230176b36" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityTaxIdentificationNumber_d2e26dbe-6d45-4e55-933e-992230176b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_944fc2b8-6f55-46bd-b652-6fad7b4d6cf7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityAddressAddressLine1_944fc2b8-6f55-46bd-b652-6fad7b4d6cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_01d90c2d-7041-4bcf-b6ee-466f8a2d3be2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityAddressAddressLine2_01d90c2d-7041-4bcf-b6ee-466f8a2d3be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eb8eaabb-59d6-4aa5-b6fd-2f9bc5b898e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityAddressCityOrTown_eb8eaabb-59d6-4aa5-b6fd-2f9bc5b898e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f2762d64-7f7d-4734-bede-ef0cae0b17c0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityAddressStateOrProvince_f2762d64-7f7d-4734-bede-ef0cae0b17c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e3c8d969-7b1f-4b1e-92f8-a6e049d52a7c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityAddressPostalZipCode_e3c8d969-7b1f-4b1e-92f8-a6e049d52a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_db23bb09-3944-4693-bfdc-f213ce3ea508" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_CityAreaCode_db23bb09-3944-4693-bfdc-f213ce3ea508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b9510b05-f90f-43c4-a51d-334dcd76e25a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_LocalPhoneNumber_b9510b05-f90f-43c4-a51d-334dcd76e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_4a721972-4a3a-4270-bf15-00f611537ee6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_WrittenCommunications_4a721972-4a3a-4270-bf15-00f611537ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_75f1a852-847c-4195-82d8-6394fbe9a0d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_SolicitingMaterial_75f1a852-847c-4195-82d8-6394fbe9a0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e2106670-fa9a-42c1-aad3-cd6bc7b70862" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_PreCommencementTenderOffer_e2106670-fa9a-42c1-aad3-cd6bc7b70862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2532eae4-7836-4dff-845b-876a19fa4ea7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2532eae4-7836-4dff-845b-876a19fa4ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_25ce07fd-2bc0-4380-b0f8-15da76b4fadb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_Security12bTitle_25ce07fd-2bc0-4380-b0f8-15da76b4fadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eb4be916-8415-49b5-9b66-f8a42e83fc5c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_TradingSymbol_eb4be916-8415-49b5-9b66-f8a42e83fc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a07296e8-3f30-4d67-afa8-731c1eaed39a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_SecurityExchangeName_a07296e8-3f30-4d67-afa8-731c1eaed39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1f9dc636-0e1b-4be0-b187-70dacdce8fef" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityEmergingGrowthCompany_1f9dc636-0e1b-4be0-b187-70dacdce8fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd64e57a-cecc-475e-b3d2-615f0e2783ba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_EntityCentralIndexKey_fd64e57a-cecc-475e-b3d2-615f0e2783ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_086c86e0-5eac-4ce0-8894-0c6fc8c631d9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7e8262b4-e9fd-4c4a-a299-e6566f046b6f" xlink:to="loc_dei_AmendmentFlag_086c86e0-5eac-4ce0-8894-0c6fc8c631d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>c4tlogo1.jpg
<TEXT>
begin 644 c4tlogo1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  :D# 2(  A$! Q$!_\0
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M?XM?#=/"OA^_L4O]'V26,,4ZLL6Q=FQ@,D J2OL<9Z5\=Q_LK_$JXUK^SO\
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MK-T#Q)IGBG3_ +=I-[%?VFXIYL1R-PQD?J*TJ "BBB@ HHHH **** "BBB@
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M_(@>(O\ KPF_] - 'D/[//C31? OP/BO];OH[*W-[,J[LEG;"G"J.2:W]/\
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M\40C6?$.K,;I7ODW"!=V5*J1P3@'/I@#%>J>)/A_X=\7:>UGJVCVEW!SMW1
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M#?VT+?*V1E947)(1L$8/0JPR<9K\N]6\-ZII.K-IEYI]S;:@K[#;21,)-Q.
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MT\!60ML%P@/ STR!D8/!!Q0!E?\ #.?BG_HK6O?^1O\ X_6-XN^ =WI^BO\
M\)+\8-1BTJ9EC<:AO\IV^\%(:?!/RY_"MF']H[6M!ACM/$W@35H-5507^RH3
M&PQ]X9'&3GCFL>_\(^./V@O$%@_B73W\+^#[1_-^QLQ$LW0]."21QD@!<GOP
M0#>^,&FVNC_LN_8;*]74K.VM+"*&\C&%F198@' R>".>IZUZ7\+_ /DFOA7_
M +!5K_Z*6N<^/OAV[UCX/:KI6D64EU<'[.L5O F3M6:,G 'H 3^%=3\.[.?3
M_ /ANUNHF@N8=.MXY8I!AD81J"#[@T >+^+KAM#_ &LO#UU=6N;:]M5@AFD
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M%%%>@>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X5\+_^3C/B/_US3^:5[K7(^'_AKI_AWQQKOBB"YN9+S5U5989"OEIC
M'W<#/8=2:ZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Feb. 26, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 26,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">C4 THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5617627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">490 Arsenal Way,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-0700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CCCC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001662579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cccc-20260226.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://c4therapeutics.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cccc-20260226.htm">cccc-20260226.htm</File>
    <File>cccc-20260226.xsd</File>
    <File>cccc-20260226_lab.xml</File>
    <File>cccc-20260226_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cccc-20260226.htm": {
   "nsprefix": "cccc",
   "nsuri": "http://c4therapeutics.com/20260226",
   "dts": {
    "inline": {
     "local": [
      "cccc-20260226.htm"
     ]
    },
    "schema": {
     "local": [
      "cccc-20260226.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cccc-20260226_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cccc-20260226_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://c4therapeutics.com/role/CoverPageDocument",
     "longName": "0000001 - Document - Cover Page Document",
     "shortName": "Cover Page Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cccc-20260226.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cccc-20260226.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://c4therapeutics.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-26-011971-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-011971-xbrl.zip
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MR@3UJP^0"\E?O]-_,J_Q_U!+ P04    "  X.5I<?IQ\J&P"   E!P  $0
M &-C8V,M,C R-C R,C8N>'-DS51=3]LP%'WOK_#R/#>?94U%BS00TJ1N0PPT
MWB;'N4DM$CNS'5K^/;8;4TH'6O>T/#GWGG._?*Y/SS9M@QY *B;X/(C'48"
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M/AR6<(I2*$(<0@ YX@ +I@"1A +(!-10<113-A1+^#.QO+K/AV,)!V#IY/Z
M6'89/PB6\"A8PI^/)73!$@[ <G,3[Y5YZY2%2E .(< DLJ=ZD !$1/9GK1(&
M8Q&&(>]-8CWPD>%[NL';:KG?OEY9WP^7KR$WGOIY\;I#O9[XH!O3JT"CWX]>
M3[_M-O3&ZQZ__6'1*A2KS@W$7*&(D! D$8&K:U0(,7T)IC!."54\3%5?$.J!
MCPQ"=7ABM1S/DC2\[R?!UY$;"3W-N/WF24OF?C]Y4@\TWB^>M*3?^,&3MM=W
MH5"OJ.DBWT]?;9[)5C\B>_KJ_U!+ P04    "  X.5I<@(AN<N(&   @,P
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MQ L5G$3T+^W-64"MBEC<;5#N)Q(X<(4CQNR'NS,)&6[ A !B#.>"LEPYH?:
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M(#,'I\9J.(EI8%O>U+8$ZUFW>'+@>]L-/78&@L"']?A8L&-Q*QQO1B+BS@8
M?O%"^!FA-/)\UC--X0"T47+T9C/?N^7.+V^;W2. IA^$[ L/;;SUV O@"MME
MX42P+Q,>"&:P\\OSP<7-UW-VX\?KG0/<[9DCV/D<'COE\2T*>V=P# :7T0Y?
M-_PE$/2A.KPW8EF,P+'[WG0(%!G:GBLA/W!\#K_S*1\R^.S&Y^9W!N@Z=6W
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M"X]<QIB&J+P3H$3AWV&L(*,9/%($U769Y.71^<O;CF'4CKX)-@49P5! V".
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MA51!2SM)TO^JYN=?F<83K*G\064M5OV\T_5J+2V;AAO?U9O5;OR)AL6Z6"\
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M*G08%,P6'82>$^^B8G(Y+UG="U(VB>,NC8% YX_&A5E^-$9GSL;Y#CB-CSX
MX0O_C,F$2(KL,:8Z)4V2S"I*8B?L!.OR%TP1\+ ="FK?VB GV-W=7=5L9&5V
M%6XN<,,.G F+H2MGGD>>+^E;FBU6@"T_Y)T0:R%M@1@GX*,J!/T>Q,/K1NI4
MCCI5D)PJ'F.V//E.3HR4UKRR0::"D\4?CY'Q43?FIFV>V7$$&%O5D1-[)N4A
M]&ZW2?Z&3$L_L!OP8N:Q1:VQ(6@U_,#U0O2JT762 DY#WX$.#!0(].E@@"2S
MBB_&L'X\GC#VP$@P4JU3EB\2HR=KU<M9H]3OFTJ.3#=:QG?#)V3H.V/QI(O
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MQZI$K"9A/%*QR2S9$\,_1/H9"E<&7IIB>)BDT5H0\90J69CGTCM2K-@ZO$)
MG\B]Q?8@!N_S]F#LTE$8QY=OI5 -*O(=%PC=$S1=]%KE=SP_A5T ANJ=%X#\
MY0O_H!P2YGNM-&Z<,2@1C(-[<\+=,;:]3,&+#6@B5L]Q\B'0E0+.C@M_U.P6
M$?^L+M#4P*V\3TYQJ)!_A^>[ /U(2E\Y6%P^)?ODR'7D(R7=H)1Q^%V10ZQ]
MI!Z3S-R=32' 4,TIE8P0U>%&X),^U@6Z8LZN/0=4QA@_ZP6!9]*TEF,**V*:
M+KZ3)F,1SV=#/R]Z%-F=9PE3M88<$O7(^I"^.L8O;UN-HV4_N+ NY3GX*SQ!
MRAF<#"<&7P-O"1<_N18N9C52?/0]?^91,AEY-')5$W^@YBG$KV'I6;<>.DZ%
M1-:9/-^FN"I&/-5:^PU7C3<%B\$6XJU-'E8LH"$,/P$>R,*Q%MY1@I4:.Y*6
MX+FW:FMWLA< H >DC[TH /T:O']M4,N^C&T%06\&>56\&O.]#P*G0LV$LT <
MQC\<@9DY<_C\T';I''33-J]*PV+E>A=9,H1MAU;\8,6M5>+67T-K^;M6O=KL
MM![\NE;5'_SNL67U5M6H-[=:]O'O&@WC>3;;7FO97PF^$L: Q6#&W;^_J;])
M12KUK!_6F$X:/%[OD4N-V3U>O$Q$2P6HA/ G9.K.CWB:A/Q2\7S"%0^?;<C-
M[V,?T\P5M<$1_3GZ">#3R,'G!_2R#"AP5$4&4"M.C_,0%L\^M2W+$:O/KC>,
MNF$^>4-&;9N&C$7:^1$8E. DIVD&!T,=S1";.0#5V)I@>G(261-,[Y[IW$O:
MJR@'-KIM#7Y:4,5/>GC\:D,@;"2Q%AAQ46*5E+NGE-MJ:T:K7D3*W5B7+"C=
M@NL2.<@$"\O#)3V1'-?8[+@K^:M0]%9O=K5:N[DAO:W&[+/*PW4MN/W#4*.K
MM6K&[C!4 !OR.>%[+$;"]^DEE#3S9RO>7W'DXE.6T='J]<9VJJ9 IM#^(J@!
M5FRKNSL$_10:GT:)3#P':Y/^IAK3?Q[];S1;6K/3+O5_<3&D-[5NI[5C_?\K
MA5*VSP(\'M!^T=S!.F'[8F2"TCI@K""X3$I-7EMFHQ#Y(*S?Q2H<-12(JBV3
M$4%\BA5V:<[HQ\GQETVP@"BHUF32<],,2[U3;7:>(6E1KS9K]>?(L-0;Y69?
MUV9?)G?5?76YF1L:(7 .UTT"-E@:,+9&)FL/@?*GX/XJ:+!-$E<;)/+6#HH6
M%F+K9CU_>-"?!5J-I^"L/8-)24';4] +14!WY6%>Q</.L=0[/W$\>>5]F3K_
M21*0NJ[5]$VC#67FO"3<71^XJ>GM3>.8)=V6=+OK ]>;6K=1$FY)N*^0<)N=
M+=/'>U&IM"O 7R;#IM7;#O(]=<]<&%VNL>LUGL@=E0*U46T6E])S[XS*M)K_
M1#4Z#:W;V;3XJZS1>4$M:&A-?<MZW1)!+Q'0J#4TH[%E+T")H1<).=6T5GU+
M%ZA ]N(K4*C9M]CQW%OL?IZ2MZZFMS<MJBP+WEY28&OU]J8:M430"YH\+4WO
M[K @L430C^K&#4TW-HW,%*]CY!7HT]/IC-M^/*32\?!]\?(U(MOWD;U*&XX&
M=1E'I95=8JC$T/:&3[M>AA**BZ"=L]#/XZA>"7!,(QQA#/O^>7S3[2BLM*U+
M#)48*C'T6C!D:(V-P[W%<T^+JCIE6[.W5"3P5YS1OU"C4RC*JS<TO:47L69E
M!\;WOB"U86B=C1ND2Z06&ZEZ4]]^^$6)U<)BM:GIW4X1L;KG18-G^')-^?*7
MI3D"VUB<^T*1!T9=TQO-]YL:HL40,4_H0NP-0NMMK5WKE@C=&X3J>E,S#*/$
MZ!YAM*NU]$;!,+KG<8%+^6(H%U^DJC%7A-MW#:QKV99K%&>-GR=W=(JS!$00
M9E^'EE+]SY-,,K1V9].ZYS(,_H+!2,UHE9,7BXL?+$1ME)7"!4900VL8.T30
MGAN,*I'T) ITS^*8VZC6,C9=;)QNHXY+G!8;IUNI\!*I!4?J-FJ_S"$]40YI
M*$;XXG5I$+"0WV]96;)O,4T#1$VKS"/M#T+K(&8:9=9A?Q"*DP Z[7J)T3W"
M:%/3.T43NC]1^V-B!,15IC]/Q^.!;NCK$U[9IO62F*F7F"DH9DJ>*2IF=L0S
M>^XR7XB0.> V/X^%LD=#43<[=W'YR*AIC4ZK8!;I$_D8)='N*='6&UIS7QWC
MDFCWE&@QG-/M%JV(M*3:DFI_%+*JZT4S$/:\DB6VPC-O_/SE;:=M&$=LR /;
ME/.E;2<*A?47,HIU@+[E1?ABT'UFQ0T/7EQ>K%7USL9.[YK'WG&DHJ3:/:;:
MQ@;=;275EE1;@!,?Z%6C75)M2;6OC6J;&U2 O S5[GG$_!O](JP*APWQL9#V
M>L"\* Q"L--QI-':QOL651'RW$N8^RM,7"B:UO66UNXTM'IMRQ'>3P*G%PJO
M/+[7)ZREV7>J:=>T5JVEZ<V?@&A*LEB;+#J&UNDVM$9SRRZLDBSVDBQ:7:W>
M-K1N=\O7>.R4+,B^^C7DL"C\:]FWOWV O^(]3[D_MEUZ>(O(0)YLB/>H0R[>
MHD#3-@!V,R^P<?;2H2\<>N_.T9UMA1,%M^Q=ZO"U]!8^##RT<I9N>7 3N;^'
MGC6'?R;AU/GM_P%02P$"% ,4    "  X.5I<3@YW'K,/  !!<@  $0
M        @ $     8V-C8RTR,#(V,#(R-BYH=&U02P$"% ,4    "  X.5I<
M?IQ\J&P"   E!P  $0              @ 'B#P  8V-C8RTR,#(V,#(R-BYX
M<V102P$"% ,4    "  X.5I<Q@_36C<*   46   %0              @ %]
M$@  8V-C8RTR,#(V,#(R-E]L86(N>&UL4$L! A0#%     @ .#E:7("(;G+B
M!@  (#,  !4              ( !YQP  &-C8V,M,C R-C R,C9?<')E+GAM
M;%!+ 0(4 Q0    ( #@Y6EQDHA=R>!X  !01 0 8              "  ?PC
M  !C8V-C+3(P,C8P,C(V>&5X>#DY,2YH=&U02P4&      4 !0!* 0  JD(
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>cccc-20260226_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cccc-20260226.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001662579</identifier>
        </entity>
        <period>
            <startDate>2026-02-26</startDate>
            <endDate>2026-02-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001662579</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2026-02-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">C4 THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39567</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">47-5617627</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">490 Arsenal Way,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Watertown,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">231-0700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">CCCC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2026-02-26</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
